DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 Bristol Myers - 2 Roche - 2 Johnson - 2 Helen Torley - 2 Jefferies - 1 Roth - 1 Roth MKM - 1
Top related locs:
U.S China American's DIS's Xenia Federal Korea Bengaluru
Top related orgs:
Bristol - 2 Bristol Myers Squibb - 2 REUTERS - 2 U.S - 2 Thomson - 2 Jefferies - 1 Barrick Gold - 1 NEM - 1

Search resuls for: "Halozyme"


6 mentions found


☆ Here are Thursday's biggest analyst calls: Tesla, Apple, Microsoft, Delta, Disney, Snowflake, Okta, Salesforce & more
  + stars: | 2024-02-29 | by ( Michael Bloom | ) www.cnbc.com   time to read: +10 min
Goldman Sachs reiterates Salesforce as buy Goldman said it's standing by its buy rating following the company's robust earnings report on Wednesday. "Multiple high-profile catalysts should double revs by FY28 & support an Outperform rating with a $54 PT." "We initiate coverage of Gates Industrial (GTES) with a Buy rating and $21 price target. The more aggressive stance follows a near week long sell-off in COLD shares following 4Q results and initial 2024 guidance." Goldman Sachs reiterates Microsoft as buy Goldman said it's standing by its buy rating after a meeting with Microsoft investor relations.
Persons: Jefferies, Roth, Roth MKM, Morgan Stanley downgrades Snowflake, Morgan Stanley, Goldman Sachs, Salesforce, Goldman, it's, TD Cowen downgrades Macy's, Telsey, TD Cowen, Wells, Needham, " Jefferies, Tesla, Coupang, Baird, Cantor Fitzgerald, Cantor, Gates, Piper Sandler, Piper, Raymond James, William Blair, Gordon Haskett downgrades, Haskett, Frank Slootman's Organizations: Jefferies, Barrick Gold, NEM, UBS, Apple, Mar, Bitdeer Technologies, BTC, Citi, United Airlines, Delta, Delta Air Lines Inc, DAL, Deere & Company, American Airlines Citi, Catalyst Watch, Reliance, Star India, JV, UBS downgrades Republic Services, Downside, RBC, Xenia Hotels, Resorts, Deutsche Bank, Deutsche, Products, Gates, NTR, LXU, UW, Bank of America, underperform Bank of America, Realty Trust, Fidelity, Korn, Microsoft, Macquarie Locations: U.S, China, American's, DIS's, Xenia, Federal, Korea
☆ Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
  + stars: | 2023-10-19 | by ( ) www.reuters.com   time to read: +2 min
Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsOct 19 (Reuters) - Bristol Myers Squibb (BMY.N) said on Thursday the injectable form of its blockbuster cancer drug Opdivo met the main goal in trial that had patients with a type of kidney cancer. "We believe this new option, given as a single injection administered in less than five minutes, could transform the treatment experience for both patients and physicians," Gina Fusaro, an executive at Bristol Myers Squibb, said. The trial also showed a non-inferior response rate to the subcutaneous drug, compared to its intravenous form. Bristol Myers now plans to discuss with regulators the next steps for submission and approval of subcutaneous injections for multiple types of cancers.
Persons: Bristol Myers, Dado Ruvic, Opdivo, Gina Fusaro, Roche, Johnson, Helen Torley, Leroy Leo, Anil D'Silva, Shinjini, Shounak Organizations: Bristol, Bristol Myers Squibb, REUTERS, Therapeutics, U.S, Thomson Locations: Bengaluru
☆ Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
  + stars: | 2023-07-28 | by ( Michael Erman | ) www.reuters.com   time to read: +5 min
Each year, Medicare will add more drugs to the list, the names of which have not yet been disclosed. Faspro, launched in 2020, already accounts for more than 80% of Darzalex revenue, which is due to rise to $9.5 billion this year. Merck previously told Reuters it expects this version of Keytruda could replace the more time consuming infusion for most patients. Keytruda revenue is expected to top $24 billion this year and could exceed $30 billion as soon as 2026, according to analyst estimates. The company has said its expects revenue from subcutaneous drugs containing hyaluronidase to drive its growth going forward.
Persons: Srdjan, Johnson, drugmakers, Bristol Myers, Roche, Biden’s, Michael DiFiore, DiFiore, Joseph Wolk, Faspro, Halozyme, Helen Torley, hyaluronidase, Michael Erman, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S, REUTERS, Wall Street, Merck & Co, Halozyme Therapeutics, Reuters, Bristol, Bristol Myers Squibb, Medicare, U.S . Centers, Medicaid Services, J, Reuters Graphics Merck, Merck, Thomson Locations: Ljubljana, Darzalex, Diego
☆ 21 stocks small-cap funds are buying the most to bet on explosive earnings growth, according to a fintech company
  + stars: | 2023-06-16 | by ( Laila Maidan | ) www.businessinsider.com   time to read: +3 min
Below is a list of small-cap stocks most held by funds and compiled by Fintel. One is the US small-cap growth stocks held by funds with mandates to invest in smaller companies that are generally worth between $250 million and $2 billion. But it also saw a 41% increase in the number of shares held by funds, which points to more bullish sentiment. However, it also saw a 14% drop in shares held by the same group, with three funds shedding their holdings. Below is a Fintel list of stocks held by funds with mandates to invest in small-cap companies.
Persons: Wilton Risenhoover, Goldman Sachs, Risenhoover Organizations: SEC, Nasdaq, New York Stock Exchange, Securities and Exchange Commission, Shoals Technologies Group Inc, Halozyme Therapeutics Inc
☆ Here are Wednesday's biggest analyst calls: Apple, Tesla, Walmart, Chevron, Lumentum, Rivian & more
  + stars: | 2023-05-10 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Barclays initiates 10X Genomics as overweight Barclays said in its initiation of the gene sequencing biotech company that it has margin expansion opportunities for 10X. Barclays reiterates Apple as equal weight Barclays said in its analysis of Apple TV+ that "incremental content spend could take some cash away from buybacks." Goldman Sachs reiterates Chevron as neutral Goldman said it's waiting for an "upstream inflection" before getting positive on Chevron shares. Bank of America reiterates Virgin Galactic as underperform Bank of America said it still sees too much uncertainty for the spaceflight company. Bank of America reiterates Rivian as buy Bank of America saidit's standing by shares of the electric vehicle company after its earnings report on Tuesday.
☆ Stocks making the biggest moves before the bell: Rivian, Airbnb, Twilio, Dutch Bros and more
  + stars: | 2023-05-10 | by ( Alex Harring | ) www.cnbc.com   time to read: +4 min
Rivian electric pickup trucks sit in a parking lot at a Rivian service center on May 09, 2022 in South San Francisco, California. Twilio — Shares of the software company slid 16% in premarket trading after Twilio's revenue forecast came in weaker than expected. Dutch Bros — Shares tumbled 7.6% after the company reported same-store sales and revenue for the first quarter that came in under expectations. The company did break even for the quarter, while analysts polled by StreetAccount expected a loss of 3 cents per share. Akamai Technologies — Shares of the cloud company rose nearly 5% in premarket trading on better-than-expected earnings and revenue for the first quarter.
0 next >>
Total: 6